| Name | Ifebemtinib |
| Description | Ifebemtinib (BI-853520) is an orally active and potent inhibitor of adhesion plaque kinase (FAK) (IC50=1 nM) with anti-tumour activity that inhibits globule formation and in situ tumour growth in malignant pleural mesotheliomas, and may be useful for the study of breast and ovarian cancer. |
| In vitro | 4T1, Py2T, and Py2T-LT cells were exposed to increasing concentrations of BI-853520 (0, 0.1, 0.5, 1, 5, and 10 μM for 4T1 cells; 1, 3, and 10 μM for Py2T and Py2T-LT cells) for 24 hours. The results demonstrate that BI-853520 reduces Y397-FAK phosphorylation in a dose-dependent and time-dependent manner[2]. |
| In vivo | In PC-3 cells, BI-853520（Ifebemtinib；0-3 μM; 2 h) resulted in a concentration-dependent reduction of the signal, with a median EC50 value of 1 nM[2]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween-80+45% Saline : 3.3 mg/mL (5.61 mM), Sonication is recommended.
DMSO : 71.4 mg/mL (121.32 mM), Sonication is recommended.
|
| Keywords | FAK |
| Inhibitors Related | Chloropyramine hydrochloride | FAK-IN-15 | FAK-IN-14 | (R)-Fangchinoline | Roslin 2 bromide | Ifebemtinib FA | APG-2449 | OXA-11 | Creosol | Y15 | PND-1186 | FAK-IN-10 |
| Related Compound Libraries | Anti-Lung Cancer Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Kinase Inhibitor Library | Tyrosine Kinase Inhibitor Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Orally Active Compound Library | Bioactive Compounds Library Max | Anti-Cancer Active Compound Library | Anti-Cancer Drug Library |
United States
